STOCKS TELEGRAPH

Tag: VBIV

  • VBI Vaccines Inc. (VBIV) Stock Dips Despite Promising Data from Covid-19 Vaccine Trial

    VBI Vaccines Inc. (VBIV) Stock Dips Despite Promising Data from Covid-19 Vaccine Trial

    VBI Vaccines Inc. (VBIV) stock prices were down by 8.5586% some time after market trading commenced on June 29th 2021, bringing the price up to USD$3.6668 earlier on in the trading day.

    Positive Trial Data

    The company announced on June 29th the positive Phase 1 data from its Phase 1/2 of its Covid-19 vaccine candidate, VBI-2902a. The trial saw the administering of the enveloped virus-like particle (eVLP) in healthy adults between the ages of 18 and 54. The 5µg dose expressed an optimized Covid-19 spike antigen, having been adjuvanted with aluminum phosphate.

    Trial Results

    It was generally well-tolerated and exhibited potent immune responses from subjects that were significantly higher than those seen in human convalescent sera. The potency of the eVLP particulate delivery platform against Covid-19 was demonstrated with the findings establishing a robust human proof-of-concept at a low dose and without the use of a next-generation adjuvant.

    Developing eVLPs

    The highly encouraging data furthers the development of the treatment that is being pushed towards commercialization with the support of the Canadian government, CEPI, and the National Research Council of Canada. The next phase of the ongoing adaptive Phase 1/2 study involved the assessment of VBI-2905a, with the commencement of this part of the trial anticipated for the third quarter of 2021.The company is also allocating resources towards developing multivalent eVLP candidates, which are designed to increase the scope of protection against Covid-19. A clinical study of one of these candidates is expected to commence in the first half of 2022.

    Details of the Trial

    The ongoing adaptive Phase 1/2 clinical study is randomized and placebo-controlled, with observers also being blind. Phase 1 assessed a 5µg dose of VBI-2902a, adjuvanted with aluminum phosphate. Treatment regimens included both one and two doses, with the second being administered 28 days after the initial jab. The Phase 1 part of the study saw a total of 61 healthy adults between the ages of 18 and 54, with no history of having been vaccinated against Covid-19.

    Future Outlook for VBIV

    With the world hurtling towards universal immunizations, VBIV is poised to continue its trajectory of success. The company is keen to usher in further growth as it continues to push for increased market penetration. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value

  • Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    As the U.S. reached 300,000 deaths connected with Covid-19, the first shots were given. The nurse in New York City was first vaccinated against COVID-19. On Monday, during the American mass vaccine drive, the first shot was rendered, which opened a new chapter in the fight against coronavirus’s pandemic.

    This week’s total number of shipments could exceed 2.9 million doses of Pfizer vaccine, which the FDA approved last Friday night for emergency use. A further 2.9 million supplies are eligible three weeks from now for recipients to receive a second dose.

    Phase 3 clinical trials found that the vaccine is 95 percent successful over a spectrum of age, ethnic and racial groups when administered in two doses. The first vaccination this week is obtained by front-line community staff and others who work with long-term care.

    BioCardia Inc. (NASDAQ:BCDA) shares were trading up 58.87% at $4.48 at the time of writing on Monday following the company reported that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules.

    BioCardia Inc. (NASDAQ:BCDA) share price went from a low point around $1.91 to briefly over $6.75 in past 52 weeks, though shares have since pulled back to $4.48. BCDA market cap has remained high, hitting $60.84M at the time of writing, giving it price-to-sales ratio of more than 200.

    Rubius Therapeutics Inc. (RUBY) last closed at $8.73, in a 52-week range of $3.35 to $14.44. Analysts have a consensus price target of $10.67.

    AnPac Bio-Medical Science Co. Ltd. (ANPC) stock soar by 35.07% to $5.70 after reporting that it has made significant progress in detecting pre-cancer diseases.

    Synlogic Inc. (NASDAQ:SYBX) Shares headed rising, higher as much as 13.39% following the announcement of advancement of SYNB1891 to combination arm dosing with PD-L1 checkpoint inhibitor in the on-going phase 1 study for the treatment of solid tumors and lymphoma. The most recent rating by Oppenheimer, on August 21, 2019, is at a Perform.

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 29.20% after gaining more than $35.33 on Monday.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.88, in a 52-week range of $0.88 to $9.02. Analysts have a consensus price target of $6.40.

    Amarin Corporation plc (AMRN) stock soar by 1.60% to $5.09 after announcing the presentation of important VASCEPA® (icosapent ethyl)-related scientific findings during the National Lipid Association (NLA) Scientific Sessions 2020. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Arvinas Inc. (NASDAQ:ARVN) Shares headed rising, higher as much as 95.06% after revealing that it is commencing an underwritten public offering of $250.0 million of its common stock. The most recent rating by Oppenheimer, on December 14, 2020, is at an Outperform.

    BioLineRx Ltd. (NASDAQ:BLRX) rose 26.97% after gaining more than $0.72 on Monday. The company on November 23, 2020 reported its financial results for the quarter ended September 30, 2020.

    Homology Medicines Inc. (FIXX) last closed at $11.97, in a 52-week range of $8.70 to $22.50.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 4.68% to $8.50. The firm is presenting at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m. ET. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    BioNTech SE (NASDAQ:BNTX) Shares headed falling, lower as much as -14.95% after the company and Pfizer Inc. (PFE) declared additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The most recent rating by BofA Securities, on December 01, 2020, is at a Neutral.

    Akebia Therapeutics Inc. (NASDAQ:AKBA) rose 10.80% after gaining more than $0.31 on Monday. The firm reported the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    Seelos Therapeutics Inc. (SEEL) last closed at $1.28, in a 52-week range of $0.42 to $1.71 after announcing the sale of a $12.0 million senior secured convertible note and shares of Seelos common stock to investors.

    VBI Vaccines Inc. (VBIV) stock soar by 6.71% to $3.34. The company recently revealed a partnership for the commercialization of VBI’s 3-antigen prophylactic hepatitis B (HBV) vaccine in the United States, Europe, and Canada, pending regulatory approvals. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy.

  • 20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    20 Trending Stocks In Biotechnology Industry You Should Consider Buying

    Investors are always looking for safe and secure investments and as a strong and profitable industry, the biotechnology industry is considered to be an attractive area of investment. This industry has experienced massive growth in recent years and is continuously adopting new technological advancements to keep pace with the fast-growing market. Biotechnology is a set of tools that uses living organisms to create or change a product, improve plants, trees, or animals, or develop microorganisms for specific uses.

    Modern Biotechnology’s main focus is on medicine. The companies in this sector are involved in the development of new treatments for various complex diseases. Technology has always been at the heart of the biotechnology industry. As the new technologies emerged with the passage of time the efficiency of companies has also improved. Similarly, technological advancements have also changed the clinical trial process.

    There are various other trends that the companies are following. Let see the top 20 companies in the biotechnology industry to get a better view:

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $11.47, in a 52-week range of $1.05 to $11.25. Analysts have a consensus price target of $17.00. Cassava Sciences Inc. (SAVA) has earlier announced the results of the Phase 2b study with its drug candidate Sumifilam, in Alzheimer’s disease. The clinical study which has received the funding by the National Institutes of Health (NIH) has shown the improvement in Alzheimer’s disease. Cassava Sciences Inc. (SAVA) market cap has remained high, hitting $242.02 M at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 10.21% to $16.94. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has revealed that the US Food and Drug Administration (FDA) has informed the company that it has some questions related to the Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial. the company said that it will halt the trial until it clear all the ambiguities of FDA.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) Shares headed rising, higher as much as 4.84%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (SRNE) has earlier revealed the results of its’ multicenter, open-label, Phase 1b Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for the Treatment of Intractable Cancer Pain at the 14th Annual Pain Therapeutics Summit. The company has reported the encouraging results from its Phase 1b study to evaluate Epidural Resiniferatoxin Injection.

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) rose 7.40% after gaining more than $0.51 on Friday. Pomerantz LLP is investigating claims on behalf of investors of Vaxart, Inc. Vaxart Inc. share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.40. Vaxart Inc.’s market cap has remained high, hitting $752.43 M at the time of writing.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) stock soar by 10.86% to $113.56. The most recent rating by H.C. Wainwright, on August 06, 2020, is at a Buy. Par Sterile Products, LLC (Par Sterile) has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.23%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (ONTX) earlier revealed that it has started the Phase 1 clinical trial in China for ON 123300 by its partner, HanX Biopharmaceuticals. Onconova has partnered with HanX Biopharmaceuticals in December 2017 for the development, registration, and commercialization of ON 123300 in China.

    Jaguar Health Inc. (NASDAQ: JAGX)

    Jaguar Health Inc. (NASDAQ: JAGX) last closed at $0.31, in a 52-week range of $0.29 to $1.38. Jaguar Health Inc. (JAGX) earlier revealed itis scheduled to participate in its first “Diarrhea Dialogues” virtual event on October 20 from 3:00 PM. The event, open to the financial and business community, will discuss the importance of supportive care for cancer patients as it relates to chronic lower GI tract distress, specifically with regard to debilitating diarrhea experienced as a result of cancer therapy.

    Zogenix Inc. (NASDAQ: ZGNX)

    Zogenix Inc. (NASDAQ: ZGNX) stock drop by -1.46% to $17.50. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. Zogenix Inc. (ZGNX) has revealed the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) Shares headed rising, higher as much as 4.04%. The most recent rating by Guggenheim, on September 14, 2020, is at a Buy. Trevena Inc. (TRVN) has earlier participated in three presentations at the virtual 2020 American College of Clinical Pharmacology (ACCP) Annual Meeting. The meetings have taken place from September 21st to 23rd, 2020.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) last closed at $3.08, in a 52-week range of $0.47 to $6.93. VBI Vaccines Inc. (VBIV) is scheduled to participate in upcoming presentations including Sci-B-Vac: Results on Ph3 Hep B vaccine, Targeting CMV for the development of effective GBM immunotherapy on September 29 and 30, 2020, respectively. It has today participated in the COVID-19 panel discussion on the topic: What existing treatments and vaccine development platforms show promise to control the rate of infection and spread?

    Brickell Biotech Inc. (NASDAQ: BBI)

    Brickell Biotech Inc. (NASDAQ: BBI) Shares headed rising, higher as much as 3.90%. The most recent rating by Lake Street, on August 28, 2020, is at a Buy. Brickell Biotech Inc. (BBI) has revealed that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. has received approval to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan for the treatment of primary axillary (underarm) hyperhidrosis.

    VYNE Therapeutics Inc. (NASDAQ: VYNE)

    VYNE Therapeutics Inc. (NASDAQ: VYNE) Shares headed falling, lower as much as -6.17%. VYNE Therapeutics Inc. (VYNE) has revealed that the Company will host a physician symposium on AMZEEQ and ZILXI™ on Thursday, October 1, 2020. VYNE market cap has remained high, hitting $271.70-M at the time of writing.

    Acorda Therapeutics Inc. (NASDAQ: ACOR)

    Acorda Therapeutics Inc. (NASDAQ: ACOR) shares were trading up 30.13% at $0.62 at the time of writing on Friday. Acorda Therapeutics Inc. (NASDAQ: ACOR) share price went from a low point around $0.42 to briefly over $3.27 in the past 52 weeks, though shares have since pulled back to $0.62. ACOR market cap has remained high, hitting $22.70M at the time of writing, giving it a price-to-sales ratio of more than 0. If we look at the recent analyst rating ACOR, H.C. Wainwright downgraded coverage on ACOR shares with a Neutral rating.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) last closed at $69.47, in a 52-week range of $13.53 to $95.21. Analysts have a consensus price target of $91.90. Moderna Inc. (MRNA) has moved up 413.45% from its 52-weeks low and moved down -327.03% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 17.30. This company’s market capitalization has remained high, hitting $25.72 billion at the time of writing.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 7.77% after gaining more than $0.15 on Friday. iBio Inc. (IBIO) share price went from a low point around $0.05 to briefly over $7.45 in the past 52 weeks, though shares have since pulled back to $2.08. iBio Inc. has moved up 4060.00% from its 52-weeks low and moved down -72.08% from its 52-weeks high.  IBIO market cap has remained high, hitting $336.61 M at the time of writing.

    Akebia Therapeutics Inc. (NASDAQ: AKBA)

    Akebia Therapeutics Inc. (NASDAQ: AKBA) rose 0.81% after gaining more than $0.02 on Friday.  In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $2.34 and a high of $13.71. It has moved up 5.98% from its 52-weeks low and moved down -8191% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 2.30. This company’s market capitalization has remained high, hitting $347.50 million at the time of writing.

    Vaccinex Inc. (NASDAQ: VCNX)

    Vaccinex Inc. (NASDAQ: VCNX) stock drop by -1.10% to $1.79. The most recent rating by BTIG Research, on September 23, 2020, is at a Neutral. Vaccinex Inc. (VCNX) share price went from a low point around $1.70 to briefly over $12.23 in the past 52 weeks, though shares have since pulled back to $1.79. VCNX has moved up 5.29% from its 52-weeks low and moved down -85.36% from its 52-weeks high.  VCNX market cap has remained high, hitting $36.19M at the time of writing.

    Ocugen Inc. (NASDAQ: OCGN)

    Ocugen Inc. (NASDAQ: OCGN) rose 2.29% after gaining more than $0.0 on Friday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $0.17 and a high of $16.80. It has moved up 78.53% from its 52-weeks low and moved down -98.19% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 3.30. This company’s market capitalization has remained high, hitting $40.03 million at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NMTR) last closed at $0.76, in a 52-week range of $0.37 to $1.22. 9 Meters Biopharma Inc. (NMTR) has moved up 106.59% from its 52-weeks low and moved down -37.33% from its 52-weeks high. Looking at its liquidity, it has a current ratio of 1.30. This company’s market capitalization has remained high, hitting $101.25 million at the time of writing.

    Clovis Oncology Inc. (NASDAQ: CLVS)

    Clovis Oncology Inc. (NASDAQ: CLVS) stock soar by 3.25% to $5.88. The most recent rating by H.C. Wainwright, on May 18, 2020, is at a Buy. Clovis Oncology Inc. (CLVS) share price went from a low point around $2.93 to briefly over $17.37 in the past 52 weeks, though shares have since pulled back to $5.88. CLVS has moved up 100.68% from its 52-weeks low and moved down -66.15% from its 52-weeks high.  CLVS market cap has remained high, hitting $502.33M at the time of writing.

     

  • 20 Trending Stocks In Biotechnology Industry That Need Your Attention

    20 Trending Stocks In Biotechnology Industry That Need Your Attention

    Biotechnology is considered to be the backbone of many industrial sectors and it makes a significant contribution to the well being of society. Every single day we saw changes in every sector as we experience advancements of knowledge and the new technological breakthroughs.  One of the industries that constantly change is the biotechnology industry.

    2020 is the year of continuous development and improvement in drug research. This industry is the leading rapidly growing sector of the economy. There are various trends in the biotechnology industry that the world should expect in the coming years such as the production of personalized medicines thanks to the advancement in genetics and continuous development and improvement in drug research.

    Let’s take a quick look at the 20 leading companies which are following new trends in the biotechnology sector:

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) shares were trading up 46.79% at $7.78 at the time of writing on Monday. Vaxart Inc. (NASDAQ: VXRT) share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.78. VXRT market cap has remained high, hitting $766.25M at the time of writing, giving it a price-to-sales ratio of more than 90.

    Vaxart Inc. has revealed that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. Vaxart Inc. also gave an update on its COVID-19 program.

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $7.75, in a 52-week range of $1.05 to $10.95. Cassava Sciences has announced the final results of a Phase 2bclinical study of Sumifilam in patients with Alzheimer’s Disease. Sumifilam is the first of a new class of drug compounds that bind to a protein called Filamin A. Cassava Sciences Inc. (SAVA) has earlier held a conference call on September 14.  Cassava Sciences Inc.’s market cap has remained high, hitting $182.51 million at the time of writing.

    Immunomedics Inc. (IMMU)

    Immunomedics Inc. (IMMU) stock soar by 97.99% to $83.65. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Gilead Sciences Inc. (NASDAQ: GILD) has earlier announced that it has decided to buy biotech company Immunomedics Inc for $21 billion. This decision will strengthen its cancer portfolio by gaining access to a promising drug.  Immunomedics Inc. (IMMU) has a total market capitalization of $19.19 billion.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares headed rising, higher as much as 17.88%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (NASDAQ: SRNE) has earlier disclosed that it has signed an exclusive license agreement with Mayo Clinic for an antibody-drug-nanoparticle albumin-bound (nab) immune complexes (ADNICs) platform targeting many types of human diseases including various solid and liquid tumors. Sorrento Therapeutics Inc. has a market cap of $1.86 billion.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) rose 13.00% after gaining more than $0.06 on Monday. Novan Provides Pipeline and Priority Development Programs Update. Novan Inc. (NOVN) gave a pipeline and priority development programs update. Novan Inc.’s share price went from a low point around $0.22 to briefly over $3.72 in the past 52 weeks, though shares have since pulled back to $0.53. Novan Inc.’s market cap has remained high, hitting $82.02 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 12.30% to $11.32. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has earlier signed a manufacturing agreement with Thermo Fisher Scientific. Thermo Fisher Scientific has signed a letter of intent to manufacture INOVIO’s DNA COVID-19 vaccine candidate INO-4800.

    Evofem Biosciences Inc. (NASDAQ: EVFM)

    Evofem Biosciences Inc. (NASDAQ: EVFM) Shares headed rising, higher as much as 11.90% after Evofem Biosciences to present data at the 2020 STD prevention Virtual Conference from Phase 2b Trial of EVO100 for prevention of Chlamydia and Gonorrhea in Women. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 9.28% after gaining more than $0.18 on Monday. iBio Inc. (AMEX: IBIO) has earlier disclosed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection. iBio revealed earlier the preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute, induced anti-SARS-CoV-2 antibodies.  iBio Inc has a market capitalization of $379.31 million.

    Clovis Oncology Inc. (CLVS)

    Clovis Oncology Inc. (CLVS) last closed at $7.00, in a 52-week range of $2.93 to $17.37. CLVS has traded up 138.91% from its 52-weeks low and traded down -59.70% from its 52-weeks high. Analysts have a consensus price target of $9.00. Clovis Oncology Inc. (CLVS) has earlier announced Oral Plenary Session Presentation at the International Gynecologic Cancer Society (IGCS)digital annual global meeting.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 1.82% to $1.12. The most recent rating by ROTH Capital, on June 20, 2016, is at a Buy. Heat Biologics Inc. (HTBX) has earlier participated in a virtual panel, entitled, “New Approaches to COVID-19: Hidden Breakthroughs,” being held on Thursday, September 10. Heat Biologics has also issued a key patent on combination platform therapy. Heat Biologics Inc. has a total market capitalization of $170.96 million.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) shares headed rising, higher as much as 12.82% after VBI Vaccines to present additional biomarker data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy. Its market capitalization has remained high, hitting $813.82 million.

    Dynavax Technologies Corporation (NASDAQ: DVAX)

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 13.37% after gaining more than $0.67 on Monday. Valneva and Dynavax have announced a Commercial supply agreement for Inactivated, adjuvanted COVID-19 vaccine. This is a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant for use in Valneva’s SARS-CoV-2 vaccine candidate, VLA2001. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valneva has the opportunity to purchase up to an additional 90 million doses through 2025.

    Zosano Pharma Corporation (NASDAQ: ZSAN)

    Zosano Pharma Corporation (NASDAQ: ZSAN) last closed at $1.72, in a 52-week range of $0.41 to $2.45. Zosano Pharma Corporation (ZSAN) is scheduled to participate in a Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020. At the conference, Zosano Pharma Corporation will present the company overview. Zosano Pharma Corporation has a total market capitalization of $138.86 million at the time of writing.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) stock soar by 7.30% to $63.67. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier named Michael Millette as Managing Director, Canada effective immediately. Michael Millette has joined Moderna Inc in August 2020 as Vice President. Moderna Inc has a total market cap of $24.37 billion at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NASDAQ: NMTR) Shares headed rising, higher as much as 12.61%. 9 Meters Biopharma Inc. (NASDAQ: NMTR) is scheduled to participate in the upcoming two conferences in September including H.C. Wainwright: 22nd Annual Global Investment Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. These two conferences are scheduled to take place on September 15 and September 23, respectively.

    Ampio Pharmaceuticals Inc. (AMEX: AMPE)

    Ampio Pharmaceuticals Inc. (AMEX: AMPE) rose 10.80% after gaining more than $0.08 on Monday. Ampio Pharmaceuticals Inc. (AMPE) has revealed positive results in the early trial for intravenous Ampion treatment for COVID-19 patients on September 9, 2020. The Phase I trial was continued in the supervision of Michael Roshon, MD, Ph.D., Chief of Staff at Penrose-St. Francis Hospital in Colorado Springs, Colorado.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) last closed at $105.80, in a 52-week range of $3.54 to $189.40. Novavax Inc. (NVAX) is scheduled to participate in the upcoming three conferences including Cantor Virtual Global Healthcare Conference, Morgan Stanley Virtual 18th Annual Global Healthcare Conference, and Leerink CyberRx Series: Vaccine Forum on September 15, 16, and 23, respectively. It has earlier participated in Citi 15th Annual BioPharma Virtual Conference, and H.C. Wainwright 22nd Annual Global Investment Conference on September 10, and 14, 2020, respectively.

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS)

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) stock soar by 5.50% to $2.11. The most recent rating by H.C. Wainwright, on July 01, 2020, is at a Buy. Marinus Pharmaceuticals Inc. (MRNS)has disclosed that it has entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of IV ganaxolone for the treatment of refractory status epilepticus (RSE).

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.28%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (NASDAQ: ONTX) has earlier participated in two virtual events including Marcus Evans Healthcare Investment Webinar on September 10 and H.C. Wainwright 22nd Annual Global Investment Conference onSeptmerb 14. It is scheduled to participate in the 2nd Annual RAS-Targeted Drug Development Conference on September 16, 2020.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) last closed at $2.08, in a 52-week range of $0.46 to $3.68. In the past 52-weeks of trading, Trevena Inc. (TRVN) stock fluctuated between the low of $0.46 and a high of $3.68. It has moved up $352.17% from its 52-weeks low and moved down -43.48% from its 52-weeks high. Its market capitalization is $306.38 million at the time of writing.

     

  • Stocks to Watch as Markets Await Fed Chairman Remarks

    Stocks to Watch as Markets Await Fed Chairman Remarks

    It’s a weak start to the markets as investors await news from the Federal Reserve Chairman on the steps that the Fed is taking to bump inflation to its set target of 2%.

    Speculation is rife that he will only offer a vague idea of the steps that the monetary policy committee will take.  This is largely due to data consistently showing underlying economic weakness.  Recent data on retail sales and consumer spending has shown that the core economic indicators are weak.

    This also comes at a time when the S&P 500 has hit record highs raising fears that the markets are overvalued at the moment. In this environment of perceived high risks, money continues to flow into big tech stocks such as Facebook and Amazon. Investors are optimistic that in the event that the market corrects, big tech has what it takes to absorb the impact.

    These stocks have already navigated the last few months of the COVID-19 pandemic well. Despite the dampened mood in the market, there are non-big tech stocks that have started the day on a high note. Some of them are as below:

    Urban Tea Inc [NASDAQ: MYT]

    Urban Tea is up by over 1000% this morning. The gains comes after the company announced its 1:10 reverse split that has now taken effect. Essentially this means that the company’s stock is now trading at 10 times the price it was trading at before the split.

    However, the split does not in any way affect the shareholding of the investors. Every investor will still hold the same percentage of the stock that they held before the stock. Through the reverse split, the company’s shares have shrunk from a total of 79,438,648 to about 7,944,211. However, the reverse split has not affected the company’s preferred shares that still hold at 5 million shares.

    Moxian Inc [NASDAQ: MOXC]

    Moxian Inc is another stock that has started the day on a high note. This comes after the company announced that it had agreed the terms for a merger with Btab Group Inc.  Under the deal, the new entity will offer 59 million of common stock, and 50 million class A shares that have restricted rights to vote. The merged entity will have a valuation of $400 million and over $40 million in revenues annually.

    VBI Vaccines Inc [NASDAQ: VBIV]

    This is another big mover this morning and has started the day up by over 30%. This comes after the company announced its pre-clinical COVID-19 program data and candidates selection for its one-dose vaccine candidate. This has created excitement around the stock in early morning trading.

     

  • 3 Biotech Stocks That Are Rallying Pre-Market

    3 Biotech Stocks That Are Rallying Pre-Market

    There was a renewed optimism in the equity markets yesterday, as hopes of a COVID-19 vaccine increased. The Dow was one of the biggest gainers and closed the day higher by 200 points. The S&P 500 and the NASDAQ also closed higher with gains of 1.34% and 0.69% respectively. Biotech stocks working on a COVID-19 vaccine, or a cure, continue to dominate in gains and are among the top gainers in pre-market trading. Some of the big movers ahead of markets opening are as below:

    Moderna Inc [NASDAQ:MRNA]

    Moderna Inc is one of the top gainers in pre-market trading and is up by 17.16% at the time of going to press. This follows the company’s data that shows hope for an effective COVID-19 vaccine. Data published by the Peer-reviewed New England Journal of Medicine showed that the company’s vaccine produced antibodies that neutralized the coronavirus in all the 45 patients, who took part in early human safety trials. Moderna is set to start a late-stage trial of this vaccine on July 27th. Positive sentiment is also driven by the fact that the U.S government is availing billions of dollars to Moderna and other companies for the delivery of 300 million vaccine doses by the beginning of 2021. Considering that the vaccine data came after hours, there is a possibility of the upside momentum continuing when the market opens.

    VBI Vaccines Inc [NASDAQ:VBIV]

    VBI Vaccines Inc is another biotech stock that is gaining upside momentum pre-market. At the time of writing, the stock is up by 14.86%.  Like Moderna, this stock is also working on a COVID-19 vaccine. In March, it announced that it was working with the National Research Council of Canada to come up with a vaccine. However, its biggest value driver is a cancer vaccine that is still in the works. This stock has been on the rise for weeks now after the company announced that it had observed partial response from its biomarker for cancer treatment. The company stated that there was a positive response in both safety and immunogenicity. With the potential for a vaccine for recurrent glioblastoma, this stock looks poised to stay on investor’s radar for some time.

    Immutep Limited [NASDAQ:IMMP]

    Immutep Limited is a top gainer pre-market and is currently up by 59.09%. These gains follow yesterday’s announcement that it had been granted a patent for ‘Antibody molecules to LAG-3 and U.S thereof’ by the U.S patent office. The patent is partly owned by Novartis AG and is valid until March 2035. The rally pre-market is an indicator of optimism in the company after this patent.